|
Name of the product: PLUSABCIR
Active ingredient: Abacavir 300 mg (as abacavir sulphate)
Dosage form: film-coated tablets
Dispensing requirements: Rx only
Argentine Industry
Composition:
Each film-coated tablet contains abacavir 300 mg (as abacavir sulphate), avicel PH 200, lactose DT, sodium starch glycolate, cellactose 80, colloidal silicium dioxide, magnesium estearate and OPADRY II HP 85G28725.
Indications:
PLUSABCIR in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection.
Contraindications:
PLUSABCIR is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or to any other component of the product. After a hypersensitivity reaction to abacavir, NEVER restart PLUSABCIR or any other product containing abacavir.
PLUSABCIR is contraindicated in patients with severe or moderate hepatic impairment.
Therapeutic action:
Antiretroviral.
Storage:
Keep at temperature between 15º and 30º C in the marketed packing.
Marketed presentations:
Packs containing 60 film-coated tablets.
Medicinal speciality authorised by the Ministry of Health.
Certificate Nº 53173
Laboratorio DOSA S.A.
Girardot 1369, (C1427AKC) Buenos Aires, Argentine
Pharmaceutical Director: María C. Terzo, Pharmacist
|